SAN DIEGO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company
that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome
analysis, announced today that the units sold in the Company’s initial public offering have separated in accordance with their
terms. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock.
At the commencement of trading today, the shares of common stock and the warrants will trade separately on the Nasdaq Capital
Market under the symbols “BNGO” and “BNGOW,” respectively. The units, which traded under the symbol “BNGOU,” will no longer be
listed.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor will there be any
sale of any securities referred to in this press release in any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Bionano Genomics
Bionano is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr
system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to
accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is
known as cytogenetics. The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis
tools.
Contacts
Company Contact:
Mike Ward, CFO
Bionano Genomics, Inc.
+1 (858) 888-7600
mward@bionanogenomics.com
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 775-5956
arr@lifesciadvisors.com
Media Contact:
Kirsten Thomas
The Ruth Group
+1 (508) 280-6592
kthomas@theruthgroup.com